In recent years, a growing body of research has suggested that targeting MEK inhibitors (MEKis), initially developed for cancer therapy, to intervene in mutational endings occurring in RASopathies is a promising therapeutic approach (Gazzin et al., 2024; Saint-Laurent et al., 2024). The gene discussed is MAP2K7; the disease is cancer.